IRMB, University Montpellier, INSERM, CHU Montpellier, Montpellier, France.
Hôpital Lapeyronie, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Montpellier, France.
Osteoarthritis Cartilage. 2019 Mar;27(3):493-503. doi: 10.1016/j.joca.2018.11.005. Epub 2018 Nov 28.
Transforming growth factor-β (TGFβ) is a major regulator of cartilage homeostasis and its deregulation has been associated with osteoarthritis (OA). Deregulation of the TGFβ pathway in mesenchymal stem cells (MSCs) has been proposed to be at the onset of OA. Using a secretome analysis, we identified a member of the TGFβ family, TGFβ-induced protein (TGFβi or βIGH3), expressed in MSCs and we investigated its function and regulation during OA.
Cartilage, bone, synovium, infrapatellar fat pad and bone marrow-MSCs were isolated from patients with OA or healthy subjects. Chondrogenesis of BM-MSCs was induced by TGFβ3 in micropellet culture. Expression of TGFβi was quantified by RT-qPCR, ELISA or immunohistochemistry. Role of TGFβi was investigated in gain and loss of function experiments in BM-MSCs and chondrocytes.
TGFβi was up-regulated in early stages of chondrogenesis and its knock-down in BM-MSCs resulted in the down-regulation of mature and hypertrophic chondrocyte markers. It likely occurred through the modulation of adhesion molecules including integrin (ITG)β1, ITGβ5 and N-cadherin. We also showed that TGFβi was upregulated in vitro in a model of OA chondrocytes, and its silencing enhanced the hypertrophic marker type X collagen. In addition, TGFβi was up-regulated in bone and cartilage from OA patients while its expression was reduced in BM-MSCs. Similar findings were observed in a murine model of OA.
Our results revealed a dual role of TGFβi during chondrogenesis and pointed its deregulation in OA joint tissues. Modulating TGFβi in BM-MSCs might be of interest in cartilage regenerative medicine.
转化生长因子-β(TGFβ)是软骨动态平衡的主要调节因子,其失调与骨关节炎(OA)有关。间充质干细胞(MSCs)中 TGFβ 途径的失调被认为是 OA 的起始点。通过分泌组分析,我们鉴定出 TGFβ 家族的一个成员,TGFβ 诱导蛋白(TGFβi 或βIGH3),在 MSCs 中表达,并研究了其在 OA 期间的功能和调节。
从 OA 患者或健康受试者中分离出软骨、骨、滑膜、髌下脂肪垫和骨髓-MSCs。在微球培养中,TGFβ3 诱导 BM-MSCs 软骨生成。通过 RT-qPCR、ELISA 或免疫组织化学定量检测 TGFβi 的表达。在 BM-MSCs 和软骨细胞中的功能获得和功能丧失实验中研究了 TGFβi 的作用。
TGFβi 在软骨生成的早期阶段上调,其在 BM-MSCs 中的敲低导致成熟和肥大软骨细胞标志物的下调。这可能是通过调节黏附分子,包括整合素(ITG)β1、ITGβ5 和 N-钙黏蛋白来实现的。我们还表明,TGFβi 在 OA 软骨细胞的体外模型中上调,其沉默增强了肥大标志物 X 型胶原。此外,TGFβi 在 OA 患者的骨和软骨中上调,而在 BM-MSCs 中的表达减少。在 OA 小鼠模型中也观察到了类似的发现。
我们的研究结果揭示了 TGFβi 在软骨生成过程中的双重作用,并指出其在 OA 关节组织中的失调。调节 BM-MSCs 中的 TGFβi 可能对软骨再生医学具有重要意义。